In stark contrast with TNBC, high levels of TILs in estrogen receptor-positive, HER2 receptor-negative (ER+HER2−) breast cancer were associated with recurrence of disease4, clinico-pathological features of dismal outcome5, and were an adverse prognostic factor in several large clinical cohorts1,6. This evidence concerns the gene ERBB2 and breast cancer.